Effects the Glycemic Index on Metabolic Risk Markers

NCT ID: NCT00695825

Last Updated: 2018-04-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-04-01

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recent population studies have shown that the glycemic index (GI) of food products is positively associated with the risk of developing type 2 diabetes and cardiovascular disease (CVD). In the pathogenesis of type 2 diabetes and CVD, inflammatory processes play a pivotal role. In a previous intervention study (11 weeks), however, we found no effects of lower-GI vs. higher-GI diets on fasting inflammatory markers in subjects with increased risk of developing the metabolic syndrome. People, however, spent most of their time in the postprandial period. Therefore, there is a need to study the postprandial effects of low-GI vs. high-GI diets. In addition, it needs to be emphasized the GI is derived from studies in lean subjects, while especially overweight and obese people suffer from metabolic aberrations related to the development of type 2 diabetes and CVD. AIM: To investigate in obese subjects the postprandial effects of a low-GI vs. high-GI food product on metabolic risk markers. A second research objective is to compare these effects with those in lean subjects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome X

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A1

Consumption of low GI food product on day 1 Consumption of high GI food product on day 2

Group Type EXPERIMENTAL

Low GI+high GI

Intervention Type DIETARY_SUPPLEMENT

Consumption of low GI food product on day 1 Consumption of high GI food product on day 2

A2

Consumption of high GI food product on day 1 Consumption of low GI food product on day 2

Group Type EXPERIMENTAL

High GI+low GI

Intervention Type DIETARY_SUPPLEMENT

Consumption of high GI food product on day 1 Consumption of low GI food product on day 2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low GI+high GI

Consumption of low GI food product on day 1 Consumption of high GI food product on day 2

Intervention Type DIETARY_SUPPLEMENT

High GI+low GI

Consumption of high GI food product on day 1 Consumption of low GI food product on day 2

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy and obese men

Exclusion Criteria

* smoking
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Maastricht University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maastricht University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ruth Vrolix, PhD

Role: PRINCIPAL_INVESTIGATOR

Maastricht University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Maastricht

Maastricht, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

073101

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Glycaemic Response Testing
NCT01536847 COMPLETED NA